These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 5728579)

  • 1. Absorption of phenylbutazone from entericcoated and regular tablets.
    Pantio M; Strandman D; Tikkanen R
    Acta Rheumatol Scand; 1968; 14(2):113-20. PubMed ID: 5728579
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of antacids on the absorption of enteric-coated phenylbutazone (butacote).
    Downie WW; Lowe JR; Pickup ME
    J Int Med Res; 1977; 5 Suppl 2():20-5. PubMed ID: 913870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of food on the absorption of phenylbutazone from a commercial 100 mg enteric-coated tablet.
    John VA; Monk JP
    J Clin Hosp Pharm; 1982 Sep; 7(3):175-9. PubMed ID: 7174832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The objective and timing of drug disposition studies, appendix IV. Phenylbutazone formulations: in vitro dissolution and in vivo performance.
    Leeson LJ; Shinal EC; Lukas G; Zak SB; Weiner M
    Drug Metab Rev; 1975; 4(2):277-84. PubMed ID: 1222684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability evaluation of an enteric-coated phenylbutazone formulation, and cross-over comparison with a sugar-coated product.
    Triggs EJ; Whyatt PL; Eckert G
    Med J Aust; 1977 Dec; 2(25):830-3. PubMed ID: 613197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Absorption of the drug-contents of enteric-coated tablets].
    Tikkanen R
    Nord Med; 1967 Nov; 78(47):1564-7. PubMed ID: 6075282
    [No Abstract]   [Full Text] [Related]  

  • 7. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.
    Van Petten GR; Feng H; Withey RJ; Lettau HF
    J Clin Pharmacol New Drugs; 1971; 11(3):177-86. PubMed ID: 5211351
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioavailability of phenylbutazone from a new enteric-coated formulation with superior dissolution characteristics.
    John VA; Goldsborough S; Morrison PJ; Rogers HJ; Spector RG; Bradbrook ID
    Biopharm Drug Dispos; 1982; 3(1):67-74. PubMed ID: 7082780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.
    Withey RJ; Feng H; Cook D; Van Petten GR; Lettau HF
    J Clin Pharmacol New Drugs; 1971; 11(3):187-96. PubMed ID: 5211352
    [No Abstract]   [Full Text] [Related]  

  • 10. The physiologic availability of phenylbutazone tablets marketed in India.
    Manek SP; Tipnis HP; Kulkarni RD
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed absorption of phenylbutazone caused by desmethylimipramine in humans.
    Consolo S; Morselli PL; Zaccala M; Garattini S
    Eur J Pharmacol; 1970 May; 10(2):239-42. PubMed ID: 5446377
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of desipramine on intestinal absorption of phenylbutazone and other drugs.
    Consolo S; Garattini S
    Eur J Pharmacol; 1969; 6(3):322-6. PubMed ID: 5799193
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies of gastric tolerance of coated alka-butazolidin tablets].
    Richter H; Atefie K; Gangl A; Thumb N
    Wien Z Inn Med; 1970; 51(9):430-6. PubMed ID: 5316365
    [No Abstract]   [Full Text] [Related]  

  • 14. Absorption of phenylbutazone from a paste formulation administered orally to the horse.
    Lees P; Higgins AJ; Mawhinney IC; Reid DS
    Res Vet Sci; 1986 Sep; 41(2):200-6. PubMed ID: 3775111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of phenylbutazone preparations in the horse.
    Rose RJ; Kohnke JR; Baggot JD
    Equine Vet J; 1982 Jul; 14(3):234-7. PubMed ID: 7106088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metabolic disposition for phenylbutazone in relation to its ulcerogenic effect in rats of different age].
    Kohút A; Nicák A
    Cesk Gastroenterol Vyz; 1971 Mar; 25(2):47-51. PubMed ID: 5574747
    [No Abstract]   [Full Text] [Related]  

  • 17. [Concentrations of phenylbutazone in the blood following use of Butazolidin ointment].
    Hansen EC; Nielsen E
    Ugeskr Laeger; 1972 Jan; 134(5):208-10. PubMed ID: 5010808
    [No Abstract]   [Full Text] [Related]  

  • 18. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations.
    Turakka H; Airaksinen MM
    Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463
    [No Abstract]   [Full Text] [Related]  

  • 19. [Biological availability and solubility of phenylbutazone].
    Krówczyński L; Jachowicz R; Wajdowicz A
    Folia Med Cracov; 1979; 21(1):141-7. PubMed ID: 396188
    [No Abstract]   [Full Text] [Related]  

  • 20. Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies.
    Maitho TE; Lees P; Taylor JB
    J Vet Pharmacol Ther; 1986 Mar; 9(1):26-39. PubMed ID: 3701913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.